Indegene IPO was subscribed a total of 1.70 times as of May 6. The retail portion was subscribed 1.56 times more than the offered bid. The non-institutional segment of the IPO was subscribed a total of 4.2 times.

Book Runners

JP Morgan is one of the book-running lead managers to the issue and it is the first time JP Morgan is participating in an IPO. Also, Kotak Mahindra Capital Company, Citigroup Global Markets India, and Nomura Financial Advisory & Securities (India) are working as the book-running lead managers. Link Intime India is the registrar for the issue.

Price Band

Indegene opened its IPO to retail investors on May 06 to collect a total of Rs 1,841.76 crore through offering fresh issue as well as an offer for sale. The bidding will close on May 08. It kept the price band in a range of Rs 430 to Rs 452 per equity share. A retail investor needs to apply for a minimum of 33 shares aggregating to Rs 14,916.

Employee Reservation

The IPO includes a reservation for employees of up to 296,209 shares for a discount of Rs 30 a piece. Further, the company has raised Rs 548.78 crore from the anchor investors by offering them 12.14 million shares.

How to apply for IPO

There are two modes through which one can apply for an IPO – online and offline

In online mode, you need to visit the broker’s app or website. There you need to search for the IPO section and select the company. After that, fill in the bid quantity or lot size then you need to choose the bid price from a given range. After that, enter your UPI ID and submit the IPO application. Now, pay the monarchy through your UPI app. 

In offline mode, you need to visit the nearest branch of your broking firm or bank. There you need to collect and fill up the ASBA application form. Then you need to give the necessary KYC details. Your funds will be blocked, and upon share allotment, the amount will be debited from the account. 

Expert’s View

Investors considering participation in Indegene’s IPO should view it through a medium to long-term lens, given its robust prospects for growth amidst increasing emphasis on quality and transparent communication in the life sciences sector. The company’s strategy to reduce debt in subsidiaries, modernize IT infrastructure, support workforce expansion, and pursue inorganic opportunities positions it well for future success. While execution and service delivery remain critical factors, Indegene’s established relationships with top global pharmaceutical companies, digital-first approach, and global delivery model provide a strong foundation for sustained growth in the years ahead, said Vishnu Kant Upadhyay, Assistant Vice President of Research & Advisory at Master Capital Services.